



Synthesis and anticancer activity of chalcone analogues with sulfonyl groups

Jovana M. Muškinja¹ · Adrijana Z. Burmudžija¹ · Dejan D. Baskić^{2,3} · Suzana L. Popović³ · Danijela V. Todorović⁴ · Milan M. Zarić⁵ · Zoran R. Ratković¹

Received: 13 July 2018 / Accepted: 21 December 2018 / Published online: 9 January 2019
© Springer Science+Business Media, LLC, part of Springer Nature 2019

Abstract

Three series of sulfonyl esters were synthesized in reactions of sulfonyl chlorides with three different phenolic chalcone analogues (dehydrozingerone (4-(4-hydroxy-3-methoxyphenyl)-3-buten-2-one), (*E*)-1-(4-hydroxy-3-methoxyphenyl)pent-1-en-3-one, and (*E*)-1-(4-hydroxy-3-methoxyphenyl)-5-methylhex-1-en-3-one). The structures of the new compounds were determined by IR, MS, and NMR methods. Screening of the new sulfonyl esters' in vitro cytotoxic activities against human epithelial cervical carcinoma (HeLa) and normal human fibroblast (MRC-5) cell lines by the MTT method was performed. The five most active were selected and further tested on HeLa, MRC-5, and MCF-7 (breast carcinoma) cell lines. The examined compounds exhibit strong in vitro anticancer activities with moderate-to-high selectivity, inducing apoptotic cell death and cell cycle arrest in both HeLa and MCF-7 cell lines, but have little to no effect on the non-cancerous MRC-5 cell line.

Keywords Apoptosis · Chalcones · Cell death · Cytotoxicity · Sulfonyl ester

Introduction

Cancer is one of the most human widespread diseases, so there is considerable scientific and commercial interest in

discovering new anticancer agents from naturally sourced products (Kinghorn et al. 2003). Many natural products and dietary components have been evaluated as potential chemopreventive agents; herbal remedies used in traditional medicine are a promising source of potentially active drugs (Rajasekar et al. 2012). Although many anticancer drugs of natural origin have been discovered, the search for new anticancer agents is still of great importance, particularly in terms of increasing their bioavailability and finding less toxic and more effective drugs.

Chalcones (*trans*-1,3-diaryl-2-propen-1-ones) are natural products of the flavonoid family; they are considered as intermediates in flavonoid biosynthesis, and are widespread in plants. These compounds are characterized by the presence of two phenyl rings linked by a three-carbon bridge that contains an α,β -unsaturated ketone fragment, forming the central core in a variety of important biological compounds (Mahapatra et al. 2015; Tseng et al. 2015). Chalcones and their derivatives have fascinated chemists due to their numerous useful biological and pharmacological properties, such as antioxidant (Vasil'ev et al. 2010; Sivakumar et al. 2011; Vogel et al. 2008), anti-inflammatory (Yadav et al. 2010; Zhang et al. 2010), antibacterial (Nielsen et al. 2004; Batovska et al. 2009; Alcaradz et al. 2000), antifungal (Lahtchev et al. 2008;

Supplementary information The online version of this article (<https://doi.org/10.1007/s00044-018-02283-4>) contains supplementary material, which is available to authorized users.

✉ Jovana M. Muškinja
jovana.muskinja@gmail.com

- ¹ Department of Chemistry, Faculty of Science, University of Kragujevac, Radoja Domanovića 12, 34000 Kragujevac, Serbia
- ² Public Health Institute Kragujevac, Nikole Pašića 1, 34000 Kragujevac, Serbia
- ³ Department of Microbiology and Immunology, Faculty of Medical Sciences, University of Kragujevac, Center for Molecular Medicine and Stem Cell Research, Svetozara Markovića 67, 34000 Kragujevac, Serbia
- ⁴ Department of Genetics, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovića 67, 34000 Kragujevac, Serbia
- ⁵ Department of Biochemistry, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovića 67, 34000 Kragujevac, Serbia




Fig. 1 Synthesis of chalcones

ElSohly et al. 2001; Gafner et al. 1996), antiviral (Trivedi et al. 2007; Phrutivorapongkul et al. 2003; Park et al. 2011), antiparasitic (Nielsen et al. 1995, 1998), anticancer (Zsoldos-Mady et al. 2006; Anto et al. 1995), antileishmanial (Chen et al. 1993, 1994; Liu et al. 2001; Li et al. 1995; Narender et al. 2005), and antitubercular activities (Hans et al. 2010; Sivakumar et al. 2007).

Classical synthesis of chalcones involves the Claisen–Schmidt condensation reaction of aryl methyl ketones with aromatic aldehydes (Fig. 1).

A well-known natural phenolic product, dehydrozingerone (4-(4-hydroxy-3-methoxyphenyl)-3-buten-2-one, **3**), is isolated from ginger root (*Zingiber officinale*), and is a very important chalcone analog, which exhibits anti-inflammatory, antioxidant, and antitumor-promoting activities (Motohashi et al. 1998).

Dehydrozingerone and its semi-chalcone analogs, with alkyl groups linked to the carbonyl groups instead of to the aromatic groups (as in standard chalcones), were prepared. These compounds have well-established biological activities, as was previously reported (Muškinja et al. 2016). Furthermore, the free phenolic groups reacted with corresponding aryl sulfonyl chlorides to form esters (Loewenthal 1959). Although aryl sulfonates are widely used as protective agents for hydroxy groups, they are highly stable and usually require drastic deprotection conditions. Compounds containing aryl sulfonate moieties have received considerable attention during the last two decades, as they are endowed with a variety of biological activities (anti-papillomavirus (Christensen et al. 2001), anti-HIV-1 (Rusconi et al. 1996), antineoplastic (Hanna et al. 1991), as well as having activities against various kinds of cancers (Betts et al. 2006; Cyr et al. 2008)).

Materials and methods

Chemistry

All starting chemicals were commercially available and used as received, except the solvents, which were purified by distillation.

Column chromatography: silica gel 60 (Merck, 230–400 mesh ASTM); TLC: silica gel 60 F₂₅₄-precoated plates (Merck); IR spectra: Perkin-Elmer Spectrum One FT-IR spectrometer with a KBr disc, ν in cm^{-1} ; NMR spectra: Varian Gemini 200 MHz spectrometer (200 MHz for ^1H

and 50 MHz for ^{13}C), using CDCl_3 as the solvent and TMS as the internal standard. ^1H - and ^{13}C -NMR chemical shifts were reported in parts per million (p.p.m.) and were referenced to the solvent peak; CDCl_3 (7.26 p.p.m. for ^1H and 76.90 p.p.m. for ^{13}C). Multiplicities were represented by s (singlet), d (doublet), t (triplet), q (quartet), and m (multiplet). Coupling constants (J) were in Hertz (Hz).

Mass spectrometry was performed using a Waters Micromass ZQ mass spectrometer and MassLynx software for control and data processing. Electro spray ionization in the positive mode was used. The electro spray capillary was set at 4.3 kV and the cone at 40 V. The ion source temperature was 125 °C, and the nitrogen flow rates were 400 and 50 l/h, for desolvation and cone gas flow, respectively. The collision energy was 40 eV. The melting point of the products was determined using a MelTemp1000 apparatus.

Chemical synthesis

General procedure for synthesis of (*E*)-2-methoxy-4-(3-oxoprop-1-enyl-3-alkyl)phenyl benzenesulfonates

Solutions of selected methyl ketones (2 mmol) in methanol (6 mL) were stirred and corresponding sulfonyl chlorides (2.4 mmol) were added. Then, triethylamine (0.6 mL) was added dropwise. The mixtures were stirred overnight at room temperature. After completion of the reactions, mixtures were poured into iced water with stirring. In some cases (for our compounds **7f**, **7g**, **8e**, **8f**, **8g**, and **9g**; see below), the formed precipitate was filtered and washed with cold diethyl ether. In other cases, when no precipitate formed, the organic layer was extracted with dichloromethane (3 × 50 mL), dried over anhydrous Na_2SO_4 and evaporated under vacuum. The residue was purified by short column chromatography on silica gel, using dichloromethane as eluent. The oil obtained usually crystallized; if not, the oily residue was dissolved in diethyl ether from which products crystallized on standing in a deepfreeze. Crude products were washed with cold ether, and 21 pure, mostly white crystals were obtained, as follows:

(*E*)-2-methoxy-4-(3-oxobut-1-enyl)phenyl benzenesulfonate (7a) Yellowish white crystals; yield: 88.7%; m.p. 84–85 °C; IR (KBr): 3075, 3009, 1666, 1626, 1585, 1371, 1198, 1116, 1091, 1031, 861 cm^{-1} ; ^1H -NMR (200 MHz, CDCl_3): δ = 2.38 (s, 3H, CH_3CO), 3.56 (s, 3H, OCH_3), 6.63 (d, 1H, J = 16.2 Hz, CH), 6.97–7.28 (m, 3H, Ar–H), 7.42 (d, 1H, J = 16.2 Hz, CH), 7.49–7.71 (m, 3H, Ar–H), 7.86–7.89 (m, 3H, Ar–H); ^{13}C -NMR (50 MHz, CDCl_3): δ = 27.5, 55.6, 111.5, 121.1, 124.5, 127.9, 128.5, 128.8, 134, 134.5, 136.1, 139.7, 141.9, 152, 197.9 (CO). ESI-MS (40 eV): m/z (%) = 332.37 (100%) [M]⁺, 141.17 (17%).

(E)-2-methoxy-4-(3-oxobut-1-enyl)phenyl 4-methylbenzenesulfonate (7b) White crystals; yield: 97.4%; m.p. 130–131 °C; IR (KBr): 3010, 2945, 1667, 1626, 1597, 1362, 1149, 1114, 1086, 1032, 856 cm⁻¹; ¹H-NMR (200 MHz, CDCl₃): δ = 2.37 (s, 3H, CH₃CO), 2.45 (s, 3H, CH₃), 3.59 (s, 3H, OCH₃), 6.63 (d, 1H, *J* = 16.2 Hz, CH), 6.99–7.09 (m, 2H, Ar-H), 7.17 (d, 1H, *J* = 8.2 Hz, Ar-H), 7.28–7.33 (m, 2H, Ar-H), 7.42 (d, 1H, *J* = 16.4 Hz, CH), 7.73–7.77 (m, 2H, Ar-H); ¹³C-NMR (50 MHz, CDCl₃): δ = 21.6, 27.5, 55.6, 111.6, 121, 124.3, 127.8, 128.5, 129.4, 133.1, 134.3, 139.8, 141.9, 145.2, 152.1, 197.9 (CO). ESI-MS (40 eV): *m/z* (%) = 346.40 (100%) [M]⁺, 155.19 (31%).

(E)-2-methoxy-4-(3-oxobut-1-enyl)phenyl 4-methoxybenzenesulfonate (7c) Yellowish white crystals; yield: 82.2%; m.p. 128–129 °C; IR (KBr): 3091, 3014, 1670, 1645, 1598, 1501, 1357, 1173, 1092, 1024, 852 cm⁻¹; ¹H-NMR (200 MHz, CDCl₃): δ = 2.37 (s, 3H, CH₃CO), 2.62 (s, 3H, OCH₃), 3.89 (s, 3H, OCH₃), 6.63 (d, 1H, *J* = 16.2 Hz, CH), 6.94–7.29 (m, 5H, Ar-H), 7.42 (d, 1H, *J* = 16.4 Hz, CH), 7.77–7.82 (m, 3H, Ar-H); ¹³C-NMR (50 MHz, CDCl₃): δ = 27.5, 55.6, 55.7, 111.6, 113.9, 121.1, 124.4, 127.4, 127.8, 130.8, 134.3, 139.9, 141.9, 152.1, 164.1, 197.9 (CO). ESI-MS (40 eV): *m/z* (%) = 362.40 (46%) [M]⁺, 171.19 (100%).

(E)-2-methoxy-4-(3-oxobut-1-enyl)phenyl 4-tert-butylbenzenesulfonate (7d) Yellowish white crystals; yield: 92%; m.p. 92–94 °C; IR (KBr): 3079, 2964, 1689, 1609, 1507, 1370, 1154, 1109, 1087, 1028, 852 cm⁻¹; ¹H-NMR (200 MHz, CDCl₃): δ = 1.35 (s, 9H, (CH₃)₃-C), 2.38 (s, 3H, CH₃CO), 3.54 (s, 3H, OCH₃), 6.64 (d, 1H, *J* = 16.2 Hz, CH), 6.97–7.28 (m, 3H, Ar-H), 7.43 (d, 1H, *J* = 16.4 Hz, CH), 7.53 (d, 2H, *J* = 8.8 Hz, Ar-H), 7.79 (d, 2H, *J* = 8.8 Hz, Ar-H); ¹³C-NMR (50 MHz, CDCl₃): δ = 27.5, 30.9, 35.3, 55.5, 111.4, 121.1, 124.6, 125.7, 127.8, 128.4, 133, 134.4, 139.8, 141.9, 152.1, 158.2, 197.9 (CO). ESI-MS (40 eV): *m/z* (%) = 388.48 (100%) [M]⁺, 197.27 (39%).

(E)-2-methoxy-4-(3-oxobut-1-enyl)phenyl 4-bromobenzenesulfonate (7e) Yellowish crystals; yield: 71.9%; m.p. 123–124 °C; IR (KBr): 3090, 2945, 1676, 1655, 1571, 1374, 1199, 1168, 1113, 1067, 831 cm⁻¹; ¹H-NMR (200 MHz, CDCl₃): δ = 2.38 (s, 3H, CH₃CO), 3.59 (s, 3H, OCH₃), 6.64 (d, 1H, *J* = 16.2 Hz, CH), 6.99–7.28 (m, 3H, Ar-H), 7.42 (d, 1H, *J* = 16.4 Hz, CH), 7.64–7.76 (m, 4H, Ar-H); ¹³C-NMR (50 MHz, CDCl₃): δ = 27.6, 55.6, 111.6, 121.1, 124.5, 128, 129.4, 129.9, 132.1, 134.7, 135.1, 139.5, 141.7, 151.8, 197.8 (CO). ESI-MS (40 eV): *m/z* (%) = 411.27 (29%) [M]⁺, 220.06 (4%), 155.19 (100%).

(E)-2-methoxy-4-(3-oxobut-1-enyl)phenyl 4-chlorobenzenesulfonate (7f) Yellowish powder; yield: 88%; m.p. 110–112 °C; IR (KBr): 3091, 2985, 1667, 1641, 1586, 1372,

1194, 1114, 1091, 1027, 857 cm⁻¹; ¹H-NMR (200 MHz, CDCl₃): δ = 2.38 (s, 3H, CH₃CO), 3.59 (s, 3H, OCH₃), 6.64 (d, 1H, *J* = 16.4 Hz, CH), 6.99–7.28 (m, 3H, Ar-H), 7.42 (d, 1H, *J* = 16.4 Hz, CH), 7.48–7.52 (m, 2H, Ar-H), 7.79–7.84 (m, 2H, Ar-H); ¹³C-NMR (50 MHz, CDCl₃): δ = 27.6, 55.5, 111.6, 121.1, 124.5, 128, 129.1, 129.9, 134.5, 134.6, 139.5, 140.8, 141.7, 151.8, 197.8 (CO). ESI-MS (40 eV): *m/z* (%) = 366.82 (100%) [M]⁺, 175.61 (36%).

(E)-2-methoxy-4-(3-oxobut-1-enyl)phenyl 4-nitrobenzenesulfonate (7g) Light beige powder; yield: 83.8%; m.p. 149–151 °C; IR (KBr): 3113, 2979, 1674, 1651, 1590, 1376, 1350, 1199, 1112, 1085, 1029, 842 cm⁻¹; ¹H-NMR (200 MHz, CDCl₃): δ = 2.38 (s, 3H, CH₃CO), 3.59 (s, 3H, OCH₃), 6.65 (d, 1H, *J* = 16.2 Hz, CH), 7.00–7.28 (m, 3H, Ar-H), 8.10 (d, 2H, *J* = 8.8 Hz, Ar-H), 8.38 (d, 2H, *J* = 8.8 Hz, Ar-H), 7.42 (d, 1H, *J* = 16.2 Hz, CH); ¹³C-NMR (50 MHz, CDCl₃): δ = 27.6, 55.6, 111.7, 121.2, 123.9, 124.5, 128.3, 129.9, 135.1, 139.2, 141.5, 141.8, 150.9, 151.6, 197.7 (CO). ESI-MS (40 eV): *m/z* (%) = 377.37 (100%) [M]⁺, 186.17 (7%).

(E)-2-methoxy-4-(3-oxopent-1-enyl)phenyl benzenesulfonate (8a) Yellowish crystals; yield: 93.1%; m.p. 80–82 °C; IR (KBr): 2979, 2876, 1669, 1629, 1400, 1287, 1188, 1113, 1088, 1035, 867 cm⁻¹; ¹H-NMR (200 MHz, CDCl₃): δ = 1.16 (t, 3H, *J* = 7.4 Hz, CH₃CH₂), 2.69 (q, 2H, *J* = 7.4 Hz, CH₃CH₂), 3.56 (s, 3H, OCH₃), 6.66 (d, 1H, *J* = 16.2 Hz, CH), 6.97–7.28 (m, 3H, Ar-H), 7.42–7.67 (m, 4H, CH, Ar-H), 7.46 (d, 1H, *J* = 16.2 Hz, CH), 7.85–7.90 (m, 2H, Ar-H); ¹³C-NMR (50 MHz, CDCl₃): δ = 8.1, 34.1, 55.6, 111.6, 120.9, 124.4, 126.8, 128.5, 128.8, 134, 134.6, 136.1, 139.6, 140.8, 151.9, 200.4 (CO). ESI-MS (40 eV): *m/z* (%) = 346.40 (100%) [M]⁺, 141.17 (24%).

(E)-2-methoxy-4-(3-oxopent-1-enyl)phenyl 4-methylbenzenesulfonate (8b) Yellowish white crystals; yield: 90.5%; m.p. 72–73 °C; IR (KBr): 2968, 2935, 1689, 1612, 1598, 1369, 1177, 1119, 1090, 1032, 851 cm⁻¹; ¹H-NMR (200 MHz, CDCl₃): δ = 1.16 (t, 3H, *J* = 7.2 Hz, CH₃CH₂), 2.45 (s, 3H, CH₃), 2.69 (q, 2H, *J* = 7.2 Hz, CH₃CH₂), 3.60 (s, 3H, OCH₃), 6.66 (d, 1H, *J* = 16.2 Hz, CH), 6.98–7.33 (m, 5H, Ar-H), 7.46 (d, 1H, *J* = 16.2 Hz, CH), 7.73–7.79 (m, 2H, Ar-H); ¹³C-NMR (50 MHz, CDCl₃): δ = 8.1, 21.6, 34.1, 55.6, 111.7, 120.9, 124.4, 126.8, 128.6, 129.4, 133.2, 134.5, 139.8, 140.8, 145.2, 152.1, 200.5 (CO). ESI-MS (40 eV): *m/z* (%) = 360.42 (100%) [M]⁺, 155.19 (44%).

(E)-2-methoxy-4-(3-oxopent-1-enyl)phenyl 4-methoxybenzenesulfonate (8c) Yellowish white crystals; yield: 83.1%; m.p. 108–109 °C; IR (KBr): 2982, 1674, 1585, 1366, 1191, 1117, 1088, 1025, 833 cm⁻¹; ¹H-NMR (200 MHz, CDCl₃): δ = 1.16 (t, 3H, *J* = 7.2 Hz, CH₃CH₂), 2.69 (q, 2H, *J* = 7.2 Hz,

CH₃CH₂), 3.62 (s, 3H, OCH₃), 3.88 (s, 3H, OCH₃), 6.66 (d, 1H, *J* = 16.2 Hz, CH), 6.94–7.28 (m, 5H, Ar–H), 7.46 (d, 1H, *J* = 16.2 Hz, CH), 7.75–7.83 (m, 2H, Ar–H); ¹³C–NMR (50 MHz, CDCl₃): δ = 8.1, 34.1, 55.6, 55.7, 111.6, 113.9, 120.9, 124.4, 126.7, 127.4, 130.8, 134.5, 139.8, 140.8, 152.1, 164, 200.4 (CO). ESI-MS (40 eV): *m/z* (%) = 376.42 (58%) [M]⁺, 171.19 (100%).

(*E*)-2-methoxy-4-(3-oxopent-1-enyl)phenyl 4-(tert-butyl)benzenesulfonate (8d) White crystals; yield: 78.7%; m.p. 120–121 °C; IR (KBr): 2972, 1662, 1595, 1370, 1190, 1110, 1087, 1030, 853 cm⁻¹; ¹H–NMR (200 MHz, CDCl₃): δ = 1.16 (t, 3H, *J* = 7.2 Hz, CH₃CH₂), 1.35 (s, 9H, 3xCH₃), 2.69 (q, 2H, *J* = 7.4 Hz, CH₃CH₂), 3.54 (s, 3H, OCH₃), 6.67 (d, 1H, *J* = 16.2 Hz, CH), 6.97–7.28 (m, 3H, Ar–H), 7.43–7.56 (m, 3H, CH, Ar–H), 7.77–7.81 (m, 2H, Ar–H); ¹³C–NMR (50 MHz, CDCl₃): δ = 8.1, 30.9, 34.1, 35.3, 55.5, 111.5, 120.9, 124.6, 125.8, 126.8, 128.4, 133, 134.5, 139.7, 140.8, 152, 158.1, 200.5 (CO). ESI-MS (40 eV): *m/z* (%) = 402.49 (100%) [M]⁺, 346.38 (14%), 197.27 (37%).

(*E*)-2-methoxy-4-(3-oxopent-1-enyl)phenyl 4-bromobenzenesulfonate (8e) White powder; yield: 84.2%; m.p. 110–111 °C; IR (KBr): 2984, 1668, 1587, 1375, 1176, 1115, 1085, 1027, 830 cm⁻¹; ¹H–NMR (200 MHz, CDCl₃): δ = 1.16 (t, 3H, *J* = 7.2 Hz, CH₃CH₂), 2.69 (q, 2H, *J* = 7.4 Hz, CH₃CH₂), 3.59 (s, 3H, OCH₃), 6.67 (d, 1H, *J* = 16.2 Hz, CH), 6.98–7.27 (m, 3H, Ar–H), 7.46 (d, 1H, *J* = 16.2 Hz, CH), 7.64–7.76 (m, 4H, Ar–H); ¹³C–NMR (50 MHz, CDCl₃): δ = 8.1, 34.2, 55.6, 111.6, 121, 124.5, 126.9, 129.4, 130, 132.1, 134.9, 135.1, 139.4, 140.6, 151.8, 200.4 (CO). ESI-MS (40 eV): *m/z* (%) = 425.29 (24%) [M]⁺, 220.06 (4%), 175.59 (33%), 155.18 (100%).

(*E*)-2-methoxy-4-(3-oxopent-1-enyl)phenyl 4-chlorobenzenesulfonate (8f) White powder; yield: 87.9%; m.p. 122–124 °C; IR (KBr): 2972, 1667, 1629, 1585, 1375, 1198, 1115, 1091, 1024, 845 cm⁻¹; ¹H–NMR (200 MHz, CDCl₃): δ = 1.16 (t, 3H, *J* = 7.4 Hz, CH₃CH₂), 2.69 (q, 2H, *J* = 7.2 Hz, CH₃CH₂), 3.60 (s, 3H, OCH₃), 6.67 (d, 1H, *J* = 16.0 Hz, CH), 6.99–7.27 (m, 3H, Ar–H), 7.46 (d, 1H, *J* = 16.2 Hz, CH), 7.42–7.52 (m, 2H, Ar–H), 7.78–7.84 (m, 2H, Ar–H); ¹³C–NMR (50 MHz, CDCl₃): δ = 8.1, 34.2, 55.6, 111.6, 121, 124.5, 126.9, 129.1, 129.9, 134.6, 134.9, 139.4, 140.6, 140.8, 151.8, 200.4 (CO). ESI-MS (40 eV): *m/z* (%) = 380.84 (90%) [M]⁺, 175.61 (100%).

(*E*)-2-methoxy-4-(3-oxopent-1-enyl)phenyl 4-nitrobenzenesulfonate (8g) Light beige powder; yield: 85.7%; m.p. 140–141 °C; IR (KBr): 2978, 2877, 1662, 1589, 1536, 1379, 1199, 1188, 1111, 1089, 1024, 848 cm⁻¹; ¹H–NMR (200 MHz, CDCl₃): δ = 1.16 (t, 3H, *J* = 7.2 Hz, CH₃CH₂),

2.69 (q, 2H, *J* = 7.4 Hz, CH₃CH₂), 3.59 (s, 3H, OCH₃), 6.68 (d, 1H, *J* = 16.2 Hz, CH), 7.00–7.28 (m, 3H, Ar–H), 7.46 (d, 1H, *J* = 16.2 Hz, CH), 8.07–8.12 (m, 2H, Ar–H), 8.35–8.40 (m, 2H, Ar–H); ¹³C–NMR (50 MHz, CDCl₃): δ = 8, 34.2, 55.6, 111.8, 121.1, 123.9, 124.4, 127.2, 129.9, 135.2, 139.1, 140.3, 141.8, 150.9, 151.6, 200.3 (CO). ESI-MS (40 eV): *m/z* (%) = 391.40 (100%) [M]⁺, 186.17 (18%).

(*E*)-2-methoxy-4-(5-methyl-3-oxohex-1-enyl)phenyl benzenesulfonate (9a) Yellow crystals; yield: 96.2%; m.p. 59–61 °C; IR (KBr): 2952, 2869, 1658, 1618, 1598, 1369, 1188, 1116, 1089, 1036, 841 cm⁻¹; ¹H–NMR (200 MHz, CDCl₃): δ = 0.97 (d, 6H, *J* = 6.8 Hz, 2xCH₃), 2.15–2.29 (m, 1H, CH), 2.53 (d, 2H, *J* = 7.0 Hz, CH₂), 3.56 (s, 3H, OCH₃), 6.65 (d, 1H, *J* = 16.2 Hz, CH), 6.97–7.27 (m, 3H, Ar–H), 7.44 (d, 1H, *J* = 16.2 Hz, CH), 7.52–7.67 (m, 3H, Ar–H), 7.86–7.89 (m, 2H, Ar–H); ¹³C–NMR (50 MHz, CDCl₃): δ = 22.6, 25.1, 49.9, 55.6, 111.6, 120.9, 124.5, 128.5, 128.8, 134, 134.6, 136.1, 139.6, 140.9, 151.9, 199.9 (CO). ESI-MS (40 eV): *m/z* (%) = 374.46 (100%) [M]⁺, 141.17 (36%).

(*E*)-2-methoxy-4-(5-methyl-3-oxohex-1-enyl)phenyl 4-methylbenzenesulfonate (9b) Yellowish powder; yield: 87.9%; m.p. 96–97 °C; IR (KBr): 2958, 2873, 1687, 1612, 1598, 1370, 1177, 1064, 1030, 856 cm⁻¹; ¹H–NMR (200 MHz, CDCl₃): δ = 0.97 (d, 6H, *J* = 6.8 Hz, 2xCH₃), 2.16–2.29 (m, 1H, CH), 2.45 (s, 3H, CH₃), 2.53 (d, 2H, *J* = 7.0 Hz, CH₂), 3.60 (s, 3H, OCH₃), 6.65 (d, 1H, *J* = 16.2 Hz, CH), 6.98–7.33 (m, 5H, Ar–H), 7.44 (d, 1H, *J* = 16.2 Hz, CH), 7.73–7.78 (m, 2H, Ar–H); ¹³C–NMR (50 MHz, CDCl₃): δ = 21.6, 22.6, 25.1, 49.9, 55.6, 111.7, 120.9, 124.4, 127.4, 128.5, 129.4, 133.1, 134.5, 139.8, 141, 145.2, 152.1, 199.9 (CO). ESI-MS (40 eV): *m/z* (%) = 388.48 (100%) [M]⁺, 155.19 (79%).

(*E*)-2-methoxy-4-(5-methyl-3-oxohex-1-enyl)phenyl 4-methoxybenzenesulfonate (9c) White crystals; yield: 88.5%; m.p. 74–75 °C; IR (KBr): 2954, 2873, 1687, 1610, 1597, 1368, 1170, 1094, 1030, 856 cm⁻¹; ¹H–NMR (200 MHz, CDCl₃): δ = 0.97 (d, 6H, *J* = 6.6 Hz, 2xCH₃), 2.15–2.29 (m, 1H, CH), 2.53 (d, 2H, *J* = 6.8 Hz, CH₂), 3.62 (s, 3H, OCH₃), 3.88 (s, 3H, OCH₃), 6.65 (d, 1H, *J* = 16.2 Hz, CH), 6.94–7.27 (m, 5H, Ar–H), 7.44 (d, 1H, *J* = 16.2 Hz, CH), 7.77–7.82 (m, 2H, Ar–H); ¹³C–NMR (50 MHz, CDCl₃): δ = 21.6, 22.6, 25.1, 49.9, 55.6, 111.7, 120.9, 124.4, 127.4, 128.5, 129.4, 133.1, 134.5, 139.8, 141, 145.2, 152.1, 199.9 (CO). ESI-MS (40 eV): *m/z* (%) = 404.48 (44%) [M]⁺, 171.19 (100%).

(*E*)-2-methoxy-4-(5-methyl-3-oxohex-1-enyl)phenyl 4-tert-butylbenzenesulfonate (9d) Yellowish crystals; yield: 86.9%; m.p. 86–87 °C; IR (KBr): 2957, 2900, 1658, 1628,

1596, 1370, 1179, 1111, 1087, 1032, 859 cm^{-1} ; $^1\text{H-NMR}$ (200 MHz, CDCl_3): $\delta = 0.97$ (d, 6H, $J = 6.6$ Hz, $2\times\text{CH}_3$), 1.35 (s, 9H, $3\times\text{CH}_3$), 2.16–2.29 (m, 1H, CH), 2.53 (d, 2H, $J = 7.0$ Hz, CH_2), 3.54 (s, 3H, OCH_3), 6.66 (d, 1H, $J = 16.2$ Hz, CH), 6.97–7.28 (m, 3H, Ar–H), 7.45 (d, 1H, $J = 16.2$ Hz, CH), 7.50–7.55 (m, 2H, Ar–H), 7.77–7.81 (m, 2H, Ar–H); $^{13}\text{C-NMR}$ (50 MHz, CDCl_3): $\delta = 22.6, 25.1, 30.9, 35.3, 49.9, 55.5, 111.5, 120.9, 124.6, 125.8, 127.3, 128.4, 133, 134.5, 139.7, 141, 152, 158.1, 199.9$ (CO). ESI-MS (40 eV): m/z (%) = 430.56 (100%) $[\text{M}]^+$, 197.27 (96%).

(E)-2-methoxy-4-(5-methyl-3-oxohex-1-enyl)phenyl 4-bromobenzenesulfonate (9e) Yellowish powder; yield: 83.9%; m.p. 114–115 °C; IR (KBr): 2952, 2868, 1659, 1598, 1586, 1377, 1187, 1115, 1086, 1033, 839 cm^{-1} ; $^1\text{H-NMR}$ (200 MHz, CDCl_3): $\delta = 0.98$ (d, 6H, $J = 6.6$ Hz, $2\times\text{CH}_3$), 2.16–2.29 (m, 1H, CH), 2.53 (d, 2H, $J = 7.0$ Hz, CH_2), 3.59 (s, 3H, OCH_3), 6.66 (d, 1H, $J = 16.2$ Hz, CH), 6.98–7.27 (m, 3H, Ar–H), 7.44 (d, 1H, $J = 16.2$ Hz, CH), 7.64–7.76 (m, 4H, Ar–H); $^{13}\text{C-NMR}$ (50 MHz, CDCl_3): $\delta = 22.6, 25.1, 50, 55.6, 111.7, 121.1, 124.5, 127.6, 129.4, 130, 132.1, 134.9, 135.1, 139.4, 140.8, 151.8, 199.8$ (CO). ESI-MS (40 eV): m/z (%) = 453.35 (21%) $[\text{M}]^+$, 220.07 (6%), 155.18 (100%).

(E)-2-methoxy-4-(5-methyl-3-oxohex-1-enyl)phenyl 4-chlorobenzenesulfonate (9f) Yellowish crystals; yield: 90.9%; m.p. 115–117 °C; IR (KBr): 2956, 2871, 1659, 1621, 1585, 1377, 1187, 1116, 1090, 1033, 844 cm^{-1} ; $^1\text{H-NMR}$ (200 MHz, CDCl_3): $\delta = 0.98$ (d, 6H, $J = 6.6$ Hz, $2\times\text{CH}_3$), 2.16–2.29 (m, 1H, CH), 2.53 (d, 2H, $J = 7.0$ Hz, CH_2), 3.59 (s, 3H, OCH_3), 6.66 (d, 1H, $J = 16.2$ Hz, CH), 6.99–7.27 (m, 3H, Ar–H), 7.40–7.52 (m, 3H, CH, Ar–H), 7.79–7.84 (m, 2H, Ar–H); $^{13}\text{C-NMR}$ (50 MHz, CDCl_3): $\delta = 22.6, 25.1, 50, 55.6, 111.7, 121, 124.5, 127.6, 129.1, 129.9, 134.6, 134.9, 139.4, 140.7, 140.8, 151.8, 199.8$ (CO). ESI-MS (40 eV): m/z (%) = 408.9 (59%) $[\text{M}]^+$, 175.61 (100%).

(E)-2-methoxy-4-(5-methyl-3-oxohex-1-enyl)phenyl 4-nitrobenzenesulfonate (9g) Beige powder; yield: 80.5%; m.p. 138–139 °C; IR (KBr): 2962, 2870, 1664, 1540, 1378, 1186, 1113, 1089, 1025, 848 cm^{-1} ; $^1\text{H-NMR}$ (200 MHz, CDCl_3): $\delta = 0.97$ (d, 6H, $J = 6.8$ Hz, $2\times\text{CH}_3$), 2.16–2.29 (m, 1H, CH), 2.53 (d, 2H, $J = 7.0$ Hz, CH_2), 3.59 (s, 3H, OCH_3), 6.67 (d, 1H, $J = 16.2$ Hz, CH), 7.00–7.28 (m, 3H, Ar–H), 7.44 (d, 1H, $J = 16.2$ Hz, CH), 8.08–8.12 (m, 2H, Ar–H), 8.36–8.40 (m, 2H, Ar–H); $^{13}\text{C-NMR}$ (50 MHz, CDCl_3): $\delta = 22.5, 25, 48.9, 55.5, 111.7, 121.1, 123.8, 124.4, 127.7, 129.8, 135.2, 139, 140.4, 141.8, 150.8, 151.5, 199.6$ (CO). ESI-MS (40 eV): m/z (%) = 419.45 (56%) $[\text{M}]^+$, 186.17 (47%).

Cytotoxicity

Cell cultures

Epithelial cervical carcinoma (HeLa), breast carcinoma (MCF-7), and the normal human fibroblast (MRC-5) cell lines were obtained from the American Type Culture Collection (Rockville, MD, USA). The cells were maintained in high glucose Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (all from Sigma, Germany). Antibiotics were omitted from the medium to avoid undesired interactions. The cells were cultivated at 37 °C in absolute humidity in an atmosphere containing 5% CO_2 and were subcultured two to three times a week.

Preparation of sulfonyl ester and control solutions

All compounds examined for cytotoxicity, including cisplatin (used as a control), were dissolved in dimethyl sulfoxide (DMSO; Fisher Scientific, UK) at a concentration of 20 mM, filtered through 0.22 mm Millipore filters and diluted appropriately with DMEM to working concentrations of 0.3, 1, 3, 10, 30, and 100 μM . The final concentration of DMSO in DMEM never exceeded 0.5% (vol/vol). All solutions were freshly prepared on the day of cell line treatment.


MTT assay

The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to determine the cytotoxicity of the compounds as previously described (Zaric et al. 2015). The cells were harvested from the culture flasks during the exponential growth phase, counted and 5×10^3 cells per well were seeded into 96-well culture plates. The cells were allowed to adhere overnight in a humidified incubator with 5% CO_2 . Afterwards, the supernatants were removed and the remaining cell monolayers were treated with 200 μL volumes of dilutions of the investigated compounds in fresh DMEM, as described above. Fresh DMEM was used as a control. A positive control containing cisplatin was used as reference drug for comparison. Controls wells were treated the same as test wells. All cells were incubated at 37 °C in an atmosphere of 5% CO_2 and absolute humidity for 24 and 48 h. Then, the cell culture media (with the investigated compounds) was removed, and 100 μL of MTT (0.5 mg/mL) was added to each well. After 2 h incubation at 37 °C, MTT solution was removed, and 150 μL of DMSO was added to dissolve the formazan crystals. Absorbance was measured with a multiplate reader (Zenyth 3100, Anthos Labtec Instruments GmbH, Austria) at 595 nm.

All compounds were examined in triplicate and repeated in three independent series. The percentage of cytotoxicity was calculated using the formula: $((A_{\text{control}} - A_{\text{test}})/A_{\text{control}}) \times 100$, where A is the absorbance determined for untreated (control) and treated (test) cells. The selectivity indexes (SI) for all examined compounds after 48 h screening were calculated using the formula: $\text{SI} = (\% \text{ cytotoxicity HeLa} / \% \text{ cytotoxicity MRC-5}) \times \% \text{ cytotoxicity HeLa}$. Also, using Microsoft Office Excel 2010, 50% inhibitory concentration (IC_{50}), i.e., the concentration required to cause toxic effects in 50% of intact cells, was calculated. Selectivity index (SI) values to identify selective anticancer cell activity were calculated by dividing the IC_{50} values of normal MRC-5 cells by the IC_{50} of HeLa cells (Joksimović et al. 2016).


Flow cytometric analysis

The Annexin V-FITC/7-AAD kit (Beckman Coulter, USA) was used according to the manufacturer's instructions to determine the type of cell death induced by the examined compounds. Briefly, HeLa and MCF-7 cells were treated with the examined compounds in concentrations corresponding to their IC_{50} values for 48 h at 37 °C in an atmosphere of 5% CO_2 and absolute humidity. The control was DMEM alone, treated the same as the examined compounds. Then, cells were collected, washed in phosphate buffered saline (PBS), and finally suspended in ice-cold binding buffer (1×10^5 cells/100 μL binding buffer). Cells were stained with 10 μL of Annexin V-FITC and 20 μL 7-AAD, and after 15 min' incubation in the dark, 400 μL of binding buffer was added. Cells were analyzed using a



Scheme 1 Synthesis of chalcone analogs **3**, **4**, and **5** from vanillin **1**

Scheme 2 Synthesis of sulfonyl esters **7**, **8**, and **9** in reactions of chalcone analogs with sulfonyl chlorides **6a–g**



flow cytometer, Cytomics FC500 (Beckman Coulter, USA), and the percentages of viable, apoptotic, and necrotic cells were evaluated using Flowing Software (<http://www.flowingsoftware.com/>). The results were presented as dot plots.

Cell cycle analysis






















HeLa and MCF-7 cells were treated with the examined compounds in concentrations corresponding to their IC_{50} values for 48 h at 37 °C in an atmosphere of 5% CO_2 and absolute humidity. The control was DMEM alone, treated the same as the examined compounds. After incubation, cells were collected into tubes, washed in PBS, and finally suspended in 1 mL of ice-cold 70% ethanol. After overnight incubation at 4 °C, cells were washed in PBS and treated with RNase A (500 $\mu\text{g}/\text{mL}$ PBS) for 30 min at 37 °C. Propidium iodide (5 μL of 10 mg/mL PBS) was added to each tube, and after 15 min' incubation in the dark, cells were assayed using a flow cytometer Cytomics FC500. The data were analyzed using FlowJo Software and the results were presented as histograms.

Results and discussion

Chemical synthesis

In continuation of our work on the synthesis of chalcone analogs, we decided to synthesize some new compounds with various sulfonyl groups and vanillin' fragments incorporated in the same molecule, starting from the easily accessible, natural product, vanillin. In the first step, using Claisen–Schmidt condensation, vanillin (**1**) was condensed with three different non-aromatic methyl ketones (acetone (**2a**), 4-methyl-2-pentanone (**2b**), and 2-butanone (**2c**)). These condensation reactions produced chalcone analogs **3**, **4**, and **5**, according to Scheme 1. Chalcone analog **3** was synthesized following a previously published procedure (Smith 1996), whereas chalcone analogs **4** and **5** were synthesized following a different method (Muškinja et al. 2016).

Table 1 Synthesized sulfonyl esters

Entry	Chalcone analogues	Sulfonyl chloride	Product	Yield (%)
1		6a		88.7
		6b		97.4
		6c		82.2
		6d		92
		6e		71.9
		6f		88
		6g		83.8
2		6a		93.1
		6b		90.5
		6c		83.1
		6d		78.7
		6e		84.2
		6f		87.9
		6g		85.7
3		6a		96.2
		6b		87.9
		6c		88.5
		6d		86.9
		6e		83.9
		6f		90.9
		6g		80.5

Synthesized chalcone analogs were used as substrates for further transformations. In reactions of their free phenolic groups with sulfonyl chlorides in ethanolic solution, triethylamine was used as a base, and corresponding sulfonyl esters **7a–g**, **8a–g**, and **9a–g** were obtained (Scheme 2). These reactions produced very high yields of sulfonyl esters (Table 1), and the products were characterized by their spectral data (IR, $^1\text{H-NMR}$ and $^{13}\text{C-NMR}$). The aim of this study was to obtain compounds which had enone systems and sulfonyl groups, as these groups are mostly responsible for cytotoxic activity against different cell lines.

Cytotoxic activities

Sulfonyl esters **7g**, **8b**, **8e**, **9a**, and **9g** demonstrate high cytotoxicity against tumor cell lines

The cytotoxic activities of the 21 examined sulfonyl esters from three groups (**7a–g**, **8a–g**, and **9a–g**) and cisplatin (each at 100 μM concentration) against HeLa cancer cells and MRC-5 non-cancerous cells were screened after 48 h




Fig. 2 Cytotoxicity of 21 sulfonyl esters and cisplatin at 100 μM concentrations against HeLa and MRC-5 cells after 48 h. The data show the percentage of cytotoxicity and are means of three independent replicates

Table 2 Cytotoxicity ($\text{IC}_{50}^{\text{a}}$ in μM) of six sulfonyl esters and cisplatin against HeLa, MCF-7, and MRC-5 cells and selectivity index (SI) values^b

Compound	HeLa			MCF-7			MRC-5	
	IC_{50} (24 h)	IC_{50} (48 h)	SI (48 h)	IC_{50} (24 h)	IC_{50} (48 h)	SI (48 h)	IC_{50} (24 h)	IC_{50} (48 h)
7g	58.8 \pm 4.2	11.6 \pm 0.9	1.6	44.7 \pm 2.7	18.4 \pm 0.9	1	>100	18.7 \pm 2.1
8b	13.8 \pm 0.6	14.5 \pm 1.3	3.9	84.4 \pm 5.5	30.6 \pm 1.9	1.9	71.4 \pm 5.2	57.1 \pm 3.3
8d	43.9 \pm 2.7	14 \pm 1.1	7.1	91.1 \pm 7.1	21.5 \pm 1.6	4.7	>100	>100
8e	98.7 \pm 6.3	56.9 \pm 4.2	1.7	>100	12.5 \pm 1.3	8	>100	>100
9a	13.5 \pm 0.9	11.3 \pm 0.8	8.9	>100	18.1 \pm 1.2	5.5	>100	>100
9g	>100	38.6 \pm 4.2	2.6	>100	41.5 \pm 2.7	2.4	>100	>100
Cisplatin ^c	25.7 \pm 1.8	8.7 \pm 1	4.9	94.1 \pm 8.3	24.5 \pm 2.2	1.7	>100	43.1 \pm 3.8

^a IC_{50} is defined as the concentration that causes a 50% cell proliferation inhibition

^bThe data represent the mean \pm SD of three independent replicates

^cUsed as a positive control

using the MTT assay (Fig. 2). Sulfonyl esters **8c** and **9b–e** displayed very low cytotoxic activity against HeLa cells. These compounds (at concentrations of 100 μM) were toxic to <70% of cancer cells after 48 h, and therefore, they were not eligible candidates for further investigation. All other examined compounds (100 μM) had very high cytotoxic activity, i.e., up to 96%. Additionally, we screened the cytotoxic activity of the sulfonyl esters against non-cancerous MRC-5 cells, and calculated the selectivity index (SI), in order to select the most effective sulfonyl esters that, at the same time, had activity against cancer cells but were the least damaging to non-cancerous cells.

Among compounds **7a–g**, sulfonyl ester **7g** had the highest SI (Table S1, supplementary materials). Also, among the other two groups of sulfonyl esters, compounds **8b**, **8e**, **8d**, **9a**, and **9g** displayed very high selective cytotoxicity against cancer cells as demonstrated by their SI values. Therefore, we decided to perform a more detailed analysis of the cytotoxic activity of these six compounds and to calculate their IC_{50} values.

All six examined sulfonyl esters (**7g**, **8b**, **8e**, **8d**, **9a** and **9g**) showed dose-dependent cytotoxic activity toward cancer cells after 24 and 48 h (the results of MTT assay after 24 and 48 h are shown in Fig. S1, supplementary materials). Their IC_{50} values against cancer cell lines (HeLa and MCF-7) and normal human fibroblast MRC-5 cells are shown in Table 2. All compounds showed high cytotoxic activity against cancer cells lines and moderate to low or no cytotoxicity against non-cancerous cells.

Compound **7g** displayed very low selectivity and high cytotoxic activity against both normal and cancer cells. Compound **8e** had the highest cytotoxicity and was four times more selective towards MCF-7 cancer cells than cisplatin, **8b** and **8d**, with an IC_{50} value of 12.5 \pm 1.3 μM and SI of 8. Also, compound **9a** was the most cytotoxic and the most selective of all the examined compounds against HeLa cells, with an IC_{50} value of 11.3 \pm 0.8 μM and SI of 8.9 after




Fig. 3 Flow cytometric analysis of Annexin V-FITC/7-AAD staining. Graphs show percentages of early apoptotic (EA), late apoptotic (LA), and necrotic cells (N) in untreated (control) and treated HeLa **a** and

MCF-7 **b** cells. Results are means \pm SD of three independent replicates. Dot plots (HeLa **c** and MCF-7 **d**) are representative of two independent analyses

48 h. Furthermore, compounds **7g**, **8e**, and **9a** showed higher cytotoxic activity against MCF-7 cells than did cisplatin under the same conditions. Also, cisplatin displayed moderate cytotoxicity against normal MRC-5 cells, with an

IC₅₀ value of $43.1 \pm 3.8 \mu\text{M}$. In contrast to cisplatin, compounds **8d**, **8e**, **9a**, and **9g** had no cytotoxic activity against normal MRC-5 cells with IC₅₀ values $> 100 \mu\text{M}$. Therefore, even though these sulfonyl esters, particularly **8d** and **9a**,




Fig. 4 Cell cycle analysis. Graphs show cell cycle distribution in untreated (control) and treated HeLa **a** and MCF-7 **b** cells. Results are the average of three independent replicates. Histograms (HeLa **c** and MCF-7 **d**) are representative of three independent analyses

had higher IC_{50} values against HeLa cells than cisplatin, they might have promising roles in the treatment of human epithelial cervical carcinoma considering their highly selective cytotoxicity toward cancer cells only.

Our synthesized sulfonyl esters were more potent anticancer agents than similar sulfonamide derivatives described previously (Ghorab et al. 2015). Esters **7g**, **8b**, **8d**, and **9a** showed high cytotoxic activity toward cancer HeLa cells

with IC_{50} values $< 15 \mu M$, and esters **7g**, **8e**, and **9a** also showed high anticancer activity toward MCF-7 cancer cells with IC_{50} values $< 19 \mu M$. Also, these sulfonyl esters had no cytotoxic activity toward normal MRC-5 cells. Therefore, the examined sulfonyl esters synthesized in the current study might be better candidates for future anticancer research compared to sulfonamide compounds researched earlier.

Benzofuran-substituted chalcone derivatives (Coskun et al. 2017) and our newly synthesized chalcone derivatives **7g**, **8b**, **8e**, **8d**, **9a**, and **9g** had similar anticancer activities against MCF-7 cancer cells. The cytotoxic activity of benzofuran-substituted chalcone against normal cells has not been reported, to our knowledge. On the other hand, compounds **8d**, **8e**, **9a**, and **9g** had no cytotoxic activity against normal MRC-5 cells.

Based on the results obtained, showing compounds **7g**, **8b**, **8e**, **9a**, and **9g** had high cytotoxicity and the best selectivity (Table 2), we examined the compounds' effects with regard to the predominant type of cell death they caused and to the cell cycle progression of HeLa and MCF-7 cells.

Sulfonyl esters **7g**, **8b**, **8e**, **9a**, and **9g** induce apoptosis and cell cycle arrest in HeLa and MCF-7 cells

Flow cytometric analysis showed the five examined sulfonyl esters, at concentrations corresponding to their IC_{50} values, induced apoptosis in both HeLa and MCF-7 cells (Fig. 3). The majority of nonviable cells were early or late apoptotic, whereas only minor percentages of cells were necrotic. While cell death due to necrosis induces the inflammatory response and, therefore, injury of surrounding tissue, apoptosis is limited to the dying cell and cause no damage to the neighboring cells. Hence, induction of apoptosis in cancer cells is the main objective of anticancer therapy. However, in cancer cells, the apoptotic machinery is deregulated. Alterations of both extrinsic and intrinsic apoptosis pathways and disturbance of the ratio of proapoptotic and antiapoptotic molecules facilitate survival of cancer cells and tumor formation and progression (Pistritto et al. 2016).

Therefore, the efficacy of antitumor therapy depends on the ability of the therapeutic agent to induce apoptosis. Except for the direct cytotoxic action of antitumor drugs, their cytostatic effects are also advantageous. It should be emphasized that in cancer cells, mechanisms that regulate cell cycle progression are often dysfunctional (Shapiro and Harper 1999). In normal cells, defects emerging from extracellular or intracellular insults result in arrest of cell cycle progression, giving repair mechanisms time to fix the defect. If the damage is irreparable, the damaged cell must

be removed, and so the apoptotic program is activated. Conversely, in cancer cells, altered regulatory molecules allow cells to proceed through the cell cycle and proliferate, despite cellular damage. Altered apoptosis and dysfunctional cell cycle regulation give cancer cells a survival advantage, irrespective of intended lifespan, absence of survival factors or presence of injury.

The results of our study showed that all five examined sulfonyl esters induced perturbation in the cell cycles of both cancer cell lines. Given that the selected cell lines have different characteristics and bear mutations in distinctive DNA regions, it can be presumed that different substances have differing effects on the two cancer cell lines. In HeLa cells, sulfonyl esters **7g**, **8b**, and **9a** arrested cells in the G2/M phase, while treatment with **8e** and **9g** resulted in increased percentages of cells in the S phase of the cell cycle. In MCF-7 cells, sulfonyl esters **7g**, **8e**, and **9a** induced G2/M arrest, whereas esters **8b** and **9g** induced higher percentages of cells in both G0/G1 and G2/M phases, indicating impediment of DNA synthesis and cell division (Fig. 4). Altogether, experimental results showed that all examined sulfonyl esters were both cytotoxic and cytostatic towards HeLa and MCF-7 cell lines, and therefore, these novel compounds should be seriously considered as potential anticancer agents.

Conclusion

Three chalcone analogs, starting from the natural product, vanillin, were prepared. The free phenolic groups in these compounds were modified by simple synthesis procedures, giving very high yields of sulfonyl esters. These esters show high in vitro anticancer activity, inducing apoptosis in human epithelial carcinoma HeLa cells and breast carcinoma MCF-7 cell lines. Importantly, these new sulfonyl esters show low or no cytotoxicity against a human fetal lung fibroblast cell line (MRC-5). Also, the examined compounds exert cytostatic action, inducing cell cycle arrest in HeLa and MCF-7 cells. The novel sulfonyl esters can be considered as a significant starting point for the development of new anticancer drugs.

Acknowledgements The authors are grateful to the Ministry of Education, Science and Technological Development of the Republic of Serbia (Grant 172034) for financial support.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

- Alcaradz LE, Blanco SE, Puig ON, Tomads F, Ferretti FH (2000) Antibacterial activity of flavonoids against methicillin-resistant *Staphylococcus aureus* strains. *J Theor Biol* 205:231–240
- Anto RJ, Sukumaran K, Kuttan G, Rao MNA, Subbaraju V, Kuttan R (1995) Anticancer and antioxidant activity of synthetic chalcones and related compounds. *Cancer Lett* 97:33–37
- Batovska D, Parushev S, Stamboliyska B, Tsvetkova I, Ninova M, Najdenski H (2009) Examination of growth inhibitory properties of synthetic chalcones for which antibacterial activity was predicted. *Eur J Med Chem* 44:2211–2218
- Betts LM, Tam NC, Kabir SMH, Langler RF, Crandall I (2006) Ether aryl sulfonic acid esters with improved antimalarial/anticancer activities. *Aust J Chem* 59:277–282
- Chen M, Christensen SB, Blom J, Lemmich E, Nadelmann L, Fich K, Theander TG, Kharazmi A (1993) Licochalcone A, a novel antiparasitic agent with potent activity against human pathogenic protozoan species of *Leishmania*. *Antimicrob Agent Chemother* 37:2550–2556
- Chen M, Christensen SB, Theander TG, Kharazmi A (1994) Antileishmanial activity of licochalcone A in mice infected with *Leishmania major* and in hamsters infected with *Leishmania donovani*. *Antimicrob Agent Chemother* 38:1339–1344
- Christensen ND, Reed CA, Culp TD, Hermonat PL, Howett MK, Anderson RA, Zaneveld LJ (2001) Papillomavirus microbicidal activities of high molecular weight cellulose sulphate, dextrane sulphate and polystyrene sulfonate. *Antimicrob Agents Chemother* 45:3427–3432
- Coskun D, Erkisa M, Ulukaya E, Coskun MF, Ari F (2017) Novel 1-(7-ethoxy-1-benzofuran-2-yl) substituted chalcone derivatives: synthesis, characterization and anticancer activity. *Eur J Med Chem* 136:212–222
- Cyr L, Langler R, Lavigne C (2008) Cell cycle arrest and apoptosis responses of human breast epithelial cells to the synthetic organosulfur compound *p*-methoxyphenyl *p*-toluenesulfonate. *Anticancer Res* 28:2753–2764
- ElSohly HN, Joshi AS, Nimrod AC, Walker LA, Clark AM (2001) Antifungal chalcones from *Maclura tinctoria*. *Planta Med* 67:87–89
- Gafner S, Wolfender JL, Mavi S, Hostettmann K (1996) Antifungal and antibacterial chalcones from *Myrica serrata*. *Planta Med* 62:67–69
- Ghorab MM, Ragab FA, Heiba HI, El-Gazzar MG, Zahran SS (2015) Synthesis, anticancer and radiosensitizing evaluation of some novel sulfonamide derivatives. *Eur J Med Chem* 92:682–692
- Hanna MA, Girges MM, Berghot MA (1991) Sulfonate ester containing (imidazol-1-yl) *N*-substituted benzenesulfonamides of anticipated antineoplastic activity. *Phosphorus Sulfur Silicon Relat Elem* 61:239–246
- Hans RH, Guantai EM, Lategan C, Smith PJ, Wan B, Franzblau SG, Gut J, Rosenthal PJ, Chibale K (2010) Synthesis, antimalarial and antitubercular activity of acetylenic chalcones. *Bioorg Med Chem Lett* 20:942–944
- Joksimović N, Baskić D, Popović S, Zarić M, Kosanić M, Ranković B, Stanojković T, Novaković SB, Davidović G, Bugarić Z, Janković N (2016) Synthesis, characterization, biological activity, DNA and BSA binding study: novel copper (II) complexes with 2-hydroxy-4-aryl-4-oxo-2-butenolate. *Dalton Trans* 45:15067–15077
- Kingham A, Farnsworth N, Soejarto D, Cordell G, Swanson S, Pezuto J, Wani M, Wall M, Oberlies N, Kroll D, Kramer R, Rose W, Vite G, Fairchild C, Peterson R, Wild R (2003) Novel strategies for the discovery of plant derived anticancer agents. *Pharm Biol* 41:53–67
- Lahtchev KL, Batovska DI, Parushev SP, Ubiyovk VM, Sibirny AA (2008) Antifungal activity of chalcones: a mechanistic study using various yeast strains. *Eur J Med Chem* 43:2220–2228
- Li R, Kenyon GL, Cohen FE, Chen X, Gong B, Dominguez JN, Davidson E, Kurzban G, Miller RE, Nuzum EO, Rosenthal PJ, McKerrow JH (1995) In vitro antimalarial activity of chalcones and their derivatives. *J Med Chem* 38:5031–5037
- Liu M, Wilairat P, Go ML (2001) Antimalarial alkoxyated and hydroxylated chalcones: structure-activity relationship analysis. *J Med Chem* 44:4443–4452
- Loewenthal HJE (1959) Selective reactions and modification of functional groups in steroid chemistry. *Tetrahedron* 6:269–303
- Mahapatra DM, Bharti SK, Asati V (2015) Anti-cancer chalcones: structural and molecular target perspectives. *Eur J Med Chem* 98:69–114
- Motohashi N, Yamagami C, Tokuda H, Konoshima T, Okuda Y, Okuda M, Mukainaka T, Nishino H, Saito Y (1998) Inhibitory effects of dehydrozingerone and related compounds on 12-O-tetradecanoylphorbol-13-acetate induced Epstein-Barr virus early antigen activation. *Cancer Lett* 134:37–42
- Muškinja J, Ratković Z, Ranković B, Kosanić M (2016) Synthesis of *o*-alkyl derivatives of dehydrozingerone analogues Kragujevac *J Sci* 38:97–106
- Narender T, Tanvir K, Shweta N, Goyal N, Gupta S (2005) Synthesis of chromenochalcones and evaluation of their in vitro antileishmanial activity. *Bioorg Med Chem* 13:6543–6550
- Nielsen SF, Boesen T, Larsen M, Schønning K, Kromann H (2004) Antibacterial chalcones-bioisosteric replacement of the 4'-hydroxy group. *Bioorg Med Chem* 12:3047–3054
- Nielsen SF, Chen M, Theander TG, Kharazmi A, Christensen SB (1995) Synthesis of antiparasitic licorice chalcones. *Bioorg Med Chem Lett* 5:449–452
- Nielsen SF, Kharazmi A, Christensen SB (1998) Modifications of the alpha,beta-double bond in chalcones only marginally affect the antiprotozoal activities. *Bioorg Med Chem* 6:937–945
- Park JY, Jeong HJ, Kim YM, Park SJ, Rho MC, Park KH, Ryu YB, Lee WS (2011) Characteristic of alkylated chalcones from *Angelica keiskei* on influenza virus neuraminidase inhibition. *Bioorg Med Chem Lett* 21:5602–5604
- Phrutivorapongkul A, Lipipun V, Ruangrunsi N, Kirtikara K, Nishikawa K, Maruyama S, Watanabe T, Ishikawa T (2003) Studies on the chemical constituents of stem bark of *Millettia leucantha*: Isolation of new chalcones with cytotoxic, anti-herpes simplex virus and anti-inflammatory activities. *Chem Pharm Bull* 51:187–190
- Pistritto G, Trisciuglio D, Ceci C, Garufi A, D'Orazi G (2016) Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. *Aging* 8:603–619
- Rajasekar S, Park DJ, Park C, Park S, Park YH, Kim ST, Choi YH, Choi YW (2012) In vitro and in vivo anticancer effects of *Lithospermum erythrorhizon* extract on B16F10 murine melanoma. *J Ethnopharmacol* 144:335–345
- Rusconi S, Moonis M, Merrill DP, Pallai PV, Neidhardt EA, Singh SK, Osburne MS, Profy AT, Jenson JC, Hirsch MS (1996) Naphthalene sulfonate polymers with CD-4 blocking and anti-human immunodeficiency virus type 1 activities. *Antimicrob Agents Chemother* 40:234–236
- Shapiro GI, Harper JW (1999) Anticancer drug targets: cell cycle and checkpoint control. *J Clin Invest* 15:1645–1653
- Sivakumar PM, Geetha Babu SM, Mukesh D (2007) QSAR studies on chalcones and flavonoids as anti-tuberculosis agents using genetic function approximation (GFA) method. *Chem Pharm Bull* 55:44–49
- Sivakumar PM, Prabhakar PK, Doble M (2011) Synthesis, antioxidant evaluation, and quantitative structure-activity relationship studies of chalcones. *Med Chem Res* 20:482–492
- Smith LR (1996) Rheosmin (“raspberry ketone”) and zingerone, and their preparation by crossed aldol-catalytic hydrogenation sequences. *Chem Educ* 1:1–18
- Trivedi JC, Bariwal JB, Upadhyay KD, Naliapara YT, Joshi SK, Pannecouque CC, Clercq ED, Shah AK (2007) Improved and

- rapid synthesis of new coumarinyl chalcone derivatives and their antiviral activity. *Tetrahedron Lett* 48:8472–8474
- Tseng CH, Tzeng CC, Hsu CY, Cheng CM, Yang CN, Chen YL (2015) Discovery of 3-phenylquinolinyl chalcone derivatives as potent and selective anticancer agents against breast cancers. *Eur J Med Chem* 97:306–319
- Vasil'ev RF, Kancheva VD, Fedorova GF, Batovska DI, Trofimov AV (2010) Antioxidant activity of chalcones: the chemiluminescence determination of the reactivity and the quantum chemical calculation of the energies and structures of reagents and intermediates. *Kinet Catal* 51:507–515
- Vogel S, Ohmayer S, Brunner G, Heilmann J (2008) Natural and non-natural prenylated chalcones: synthesis, cytotoxicity and anti-oxidative activity. *Bioorg Med Chem* 16:4286–4293
- Yadav HL, Gupta P, Pawar PS, Singour PK, Patil UK (2010) Synthesis and biological evaluation of anti-inflammatory activity of 1,3-diphenyl propenone derivatives. *Med Chem Res* 19:1–8
- Zaric M, Mitrovic M, Nikolic I, Baskic D, Popovic S, Djurdjevic P, Milosavljevic Z, Zelen I (2015) Chrysin induces apoptosis in peripheral blood lymphocytes isolated from human chronic lymphocytic leukemia. *Anti-Cancer Agents Med Chem* 15:189–195
- Zhang XW, Zhao DH, Quan YC, Sun LP, Yin XM, Guan LP (2010) Synthesis and evaluation of anti-inflammatory activity of substituted chalcone derivatives. *Med Chem Res* 19:403–412
- Zsoldos-Mady V, Csampai A, Szabo R, Meszaros-Alapi E, Pasztor J, Hudecz F, Sohar P (2006) Synthesis, structure, and in vitro anti-tumor activity of some glycoside derivatives of ferrocenyl-chalcones and ferrocenyl-pyrazolines. *Chem Med Chem* 1:1119–1125